1. Sarepta Therapeutics shares surge 20% on early data for rare disease drugs, signaling a fragile comeback after gene therapy crisis
Sarepta Therapeutics is attempting a high-stakes turnaround, with its stock soaring over 20% on the back of promising early clinical data for two new muscular dystrophy drugs. This surge represents a critical vote of confidence from investors, but it comes against the backdrop of a company still reeling from a catastro...